Modulation of carbachol-stimulated AP-1 DNA binding activity by therapeutic agents for bipolar disorder in human neuroblastoma SH-SY5Y cells

Molecular Brain Research

Volumn 72, Issue 2, 1999, Pages 138-146

  Pacheco, Mary A ^a   Jope, Richard S ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Bipolar disorder; Carbamazepine; Lithium; Phosphoinositide; Valproate

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; CARBACHOL; CARBAMAZEPINE; IONOMYCIN; LITHIUM; PROTEIN KINASE C; TRANSCRIPTION FACTOR AP 1; VALPROIC ACID;

ARTICLE; CALCIUM CELL LEVEL; CELL; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; HUMAN; HUMAN CELL; MANIC DEPRESSIVE PSYCHOSIS; NEUROBLASTOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0032862022     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(99)00215-6     Document Type: Article

References (26)

1. Asghari V., Wang J.F., Reiach J.S., Young L.T. Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Mol. Brain Res. 58:1998;95-102.
2. Bowden C.L. Role of newer medications for bipolar disorder. J. Clin. Psychopharmacol. 16:1996;48S-55S. Suppl. 1.
3. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 72:1976;248-254.
4. Chen G., Yuan P., Hawver D.B., Potter W.Z., Manji H.K. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology. 16:1997;238-245.
5. Chen G., Yuan P.X., Jiang Y.M., Huang L.D., Manji H.K. Valproate robustly enhances AP-1 mediated gene expression. Mol. Brain Res. 64:1999;52-58.
6. Dunn R.T., Frye M.S., Kimbrell T.A., Denicoff K.D., Leverich G.S., Post R.M. The efficacy and use of anticonvulsants in mood disorders. Clin. Neuropharmacol. 21:1998;215-235.
7. Friedman E., Wang H.Y. Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects. J. Neurochem. 67:1996;1145-1152.
8. C.A. Grimes, R.S. Jope, Cholinergic stimulation of early growth response-1 DNA binding activity requires protein kinase C and mitogen-activated protein kinase kinase activation and is inhibited by sodium valproate in SH-SY5Y cells. J. Neurochem., 1999, in press.
9. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
10. Jope R.S. Anti-bipolar therapy: mechanism of action of lithium. Mol. Psychiatry. 4:1999;117-128.
11. Jope R.S., Williams M.B. Lithium and brain signal transduction systems. Biochem. Pharmacol. 47:1994;429-441.
12. Jope R.S., Song L., Li P.P., Young L.T., Kish S.J., Pacheco M.A., Warsh J.J. The phosphoinositide signal transduction system is impaired in bipolar affective disorder brain. J. Neurochem. 66:1996;2402-2409.
13. Jope R.S., Song L. AP-1 and NF-kB stimulated by carbachol in human neuroblastoma SH-SY5Y cells are differentially sensitive to inhibition by lithium. Mol. Brain Res. 50:1997;171-180.
14. 2+ and inositol 1,4,5-trisphosphate mass in a human neuroblastoma cell line, SH-SY5Y. Biochem. J. 265:1990;555-562.
15. Li X., Song L., Jope R.S. Cholinergic stimulation of AP-1 and NFκB transcription factors is differentially sensitive to oxidative stress in SH-SY5Y neuroblastoma: relationship to phosphoinositide hydrolysis. J. Neurosci. 16:1996;5914-5922.
16. Manji H.K., Lenox R.H. Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse. 16:1994;11-28.
17. Mathews R., Li P.P., Young L.T., Kish S.J., Warsh J.J. Increased G alpha q/11 immunoreactivity in postmortem occipital cortex from patients with bipolar affective disorder. Biol. Psychiatry. 41:1997;649-656.
18. 2+ mobilization in the rat hippocampal slices. Neurochem. Int. 26:1995;233-238.
19. Ozaki N., Chuang D.M. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J. Neurochem. 69:1997;2336-2344.
20. Pacheco M.A., Jope R.S. Phosphoinositide signaling in human brain. Prog. Neurobiol. 50:1996;255-273.
21. Post R.M., Frye M.A., Denicoff K.D., Leverich G.S., Kimbrell T.A., Dunn R.T. Beyond lithium in the treatment of bipolar illness. Neuropsychopharmacology. 19:1998;206-219.
22. Unlap T., Jope R.S. Diurnal variation in kainate-induced AP-1 activation in rat brain: influence of glucocorticoids. Mol. Brain Res. 28:1995;193-200.
23. Unlap M.T., Jope R.S. Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells. Neuropsychopharmacology. 17:1997;12-17.
24. Weissman M.M., Leaf P.J., Tischler G.L., Blazer D.G., Karno M., Bruce M.L., Florio L.P. Affective disorders in five United States communities. Psychol. Med. 18:1988;141-153.
25. Williams M.B., Jope R.S. Circadian variation in rat brain AP-1 DNA binding activity after cholinergic stimulation: modulation by lithium. Psychopharmacology. 122:1995;363-368.
26. Yuan P.X., Chen G., Huang L.D., Manji H.K. Lithium stimulates gene expression through the AP-1 transcription factor pathway. Mol. Brain Res. 58:1998;225-230.